initial public offerings (IPOs) trading on American exchanges

Monday, November 30, 2015

58.com (WUBA) reported earnings Mon 30 Nov 2015

** charts before earnings **






** charts after earnings **






 58.com beats by $0.33, beats on revs; guides Q4 revs in-line :
  • Reports Q3 (Sep) loss of $0.50 per share, $0.33 better than the Capital IQ Consensus of ($0.83); revenues rose 195.7% year/year to $212.9 mln vs the $201.72 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q4, sees Q4 revs of $240-245 mln vs. $242.12 mln Capital IQ Consensus Estimate.

Saturday, November 28, 2015

CytomX Therapeutics (CTMX) began trading on the NASDAQ on 8 Oct 2015




Address

343 Oyster Point Blvd., Suite 100
SOUTH SAN FRANCISCO, CA 94080
United States 

Key stats and ratios

Q2 (Jun '15)2014
Net profit margin-214.10%-597.01%
Operating margin-271.27%-586.27%
EBITD margin--570.85%
Return on average assets-17.43%-69.48%
Return on average equity--
Employees61

Description

CytomX Therapeutics, Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs, which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company's pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company's additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.

Wednesday, November 25, 2015

Qunar.com (QUNR) reported earnings Wed 25 Nov 2015

** charts before earnings **







** charts after earnings **






Qunar beats by $0.02, beats on revs; guides Q4 revs in-line :
  • Reports Q3 (Sep) loss of $0.74 per share, $0.02 better than the Capital IQ Consensus of ($0.76); revenues rose 155.5% year/year to $208.5 mln vs the $186.14 mln Capital IQ Consensus.
    • Mobile revenues for the third quarter of 2015 were RMB975.5 million ($153.5 million), an increase of 381.3% year-on-year, representing 73.6% of total revenues, compared to 40.4% in the corresponding period of 2014.
    • Total Estimated Flight Ticket volume and Total Estimated Hotel Room-night volume for the third quarter of 2015 were 33.9 million and 22.0 million, respectively, an increase of 49.4% and 119.8% year-on-year.
  • Co issues in-line guidance for Q4, sees Q4 revs of +105-125% YoY to ~$170-187 mln vs. $183.20 mln Capital IQ Consensus Estimate.

Thursday, November 19, 2015

Square (SQ) began trading on the NYSE on 19 Novemebr 2015






Natural Grocers by Vitamin Cottage (NGVC) reported earnings Thu 19 Nov 2015 (after close)

** charts before earnings **


  





** charts after earnings **



Natural Grocers reports EPS in-line, revs in-line; guides FY16 EPS below consensus :
  • Reports Q4 (Sep) earnings of $0.13 per share, in-line with the Capital IQ Consensus of $0.13; revenues rose 19.7% year/year to $162.4 mln vs the $161.3 mln Capital IQ Consensus.
  • Co issues downside guidance for FY16, sees EPS of $0.79-0.83 vs. $0.85 Capital IQ Consensus Estimate. Its FY15 guidance also includes 23 new stores, 4 relocations, 2 remodels, 5-7% dail average comps growth, 7.8-8% EBITDA as % of sales, 2.3-2.5% net income as % of sales, and $54-56 mln in CapEx.

Match Group (MTCH) began trading on the NASDAQ on 19 Nov 2015

The Match Group raised just under $400m in its initial public offering after pricing shares at the low end of the company’s projected range of $12 to $14.

The New York-based dating company, which is being floated by Barry Diller’s IAC, sold 33.3 m shares at $12 a piece. It also granted its underwriters a 30-day option to purchase another 5m shares.






A portion of the funds raised in the offering will be used to repay debt to IAC and as a dividend to the parent company, with the remainder going to general corporate purposes. IAC will remain Match’s largest shareholder.

Match’s IPO comes at a testing time for companies seeking to tap public markets. Also on Wednesday, Square, the payments company, priced its IPO at $9 a share, below the $11 to $13 range the company had indicated in its investor roadshow.

The average year-to-date return for 2015 IPOs is a loss of 5.5 per cent, according to Renaissance Capital, a manager of IPO-focused exchange traded funds.

Match has been the fastest growing part of IAC in recent years. The company boasts 59m monthly active users and 4.7m paid subscribers across its properties, which include Match.com, Tinder, OkCupid and PlentyOfFish.

Its revenues rose 11 per cent to $888.3m in 2014 and net earnings climbed 17 per cent to $148.4m.
In the 12 months through September, the company generated $1.02bn in revenue, mainly through subscription fees for its various dating websites and apps.

But analysts have warned that its growth may not continue. Match has recently begun charging users for premium features on Tinder, but the broad availability of it and other free online dating services may be a drag on paid subscriptions.

Nimble Storage (NMBL) reported earnings on Thur 11/19/15 (a/h)

** charts after earnings **





Sunday, November 15, 2015

Kite Pharma (KITE) reported earnings Thur 12 Nov 2015

** charts before earnings **






** charts after earnings **






Kite Pharma beats by $0.02, beats on revs :
  • Reports Q3 (Sep) loss of $0.38 per share, $0.02 better than the Capital IQ Consensus of ($0.40); revenues rose 50900.0% year/year to $5.1 mln vs the $4.67 mln Capital IQ Consensus.
  • Kite's guidance remains unchanged. Kite expects to burn between $100 million and $125 million in cash for the full year 2015, which includes both operating expenses and capital expenditures. This guidance does not include cash inflows or outflows for business development activities.
  • "Our ZUMA-1 trial is enrolling patients with aggressive, refractory non-Hodgkin's lymphoma, while our ZUMA-2 trial is enrolling patients with relapsed or refractory mantle cell lymphoma. We also plan to initiate two additional pivotal studies of KTE-C19 in patients with acute lymphoblastic leukemia prior to the end of this year. We look forward to reporting data from these trials in 2016 with the goal of filing our first Biologics License Application by the end of 2016."

Saturday, November 14, 2015

Planet Fitness (PLNT) reported earnings Thur 12 Nov 2015

** charts before earnings **





** charts after earnings **







 Planet Fitness beats by $0.01, beats on revs; guides FY15 EPS & revs above consensus  :
  • Reports Q3 (Sep) earnings of $0.10 per share, $0.01 better than the Capital IQ Consensus of $0.09; revenues rose 8.4% year/year to $68.8 mln vs the $66.6 mln Capital IQ Consensus.
  • System-wide same store sales increased 6.9%.
  • Co issues upside guidance for FY15, sees EPS of $0.51-0.52 vs. $0.47 Capital IQ Consensus Estimate; sees FY15 revs of $318-321 mln vs. $314.86 mln Capital IQ Consensus Estimate.
  • Sees FY15 System-wide same store sales growth of 7.0-7.5%.